Karachi: The Board of Directors of IBL Healthcare Limited has released the company's audited financial statements for the fiscal year ending June 30, 2026, revealing a robust financial performance despite prevailing economic challenges. The report, dated October 6, 2026, highlights the company’s resilience in the face of external market pressures.
IBL Healthcare, primarily involved in marketing, selling, and distributing healthcare and pharmaceutical products, reported a 7% increase in net revenue for the year, reaching PKR 4.61 billion, up from PKR 4.32 billion in the previous fiscal year. This growth is attributed to enhanced market availability, strategic promotions, and successful execution of government tenders.
Gross profit for the year rose by 14% to PKR 1.64 billion, with an improved gross margin of 35.7%, compared to 33.5% in the previous year. This enhancement was driven by portfolio and mix improvements, calibrated pricing strategies, and stricter governance of trade terms.
Operating expenses saw a 21% increase owing to inflationary pressures and intensified marketing and sales promotion activities. Additionally, a net impairment charge on financial assets amounted to PKR 11 million, compared to none the previous year. Finance costs, however, decreased by 29% to PKR 43 million.
According to information available from the Pakistan Stock Exchange (PSX), IBL Healthcare's profit before levies and income tax increased by 6% to PKR 401 million. The effective tax rate remained steady at 45%, incorporating a super tax charge of PKR 19.6 million as per a Federal Constitutional Court judgment earlier in the year.
Despite these challenges, profit after tax rose by 6% to PKR 220 million, and earnings per share increased to Rs. 2.24, reflecting a restated figure of Rs. 2.11 from the previous year due to a bonus share issuance. The company’s cash and bank balances significantly improved from PKR 209 million to PKR 727 million, highlighting enhanced working-capital efficiency.
IBL Healthcare is a subsidiary of The Searle Company Limited, which held 68,962,827 shares as of June 30, 2026.